Central to terminal exhaustion is the accumulation of defective mitochondria within T cells—organelles that conventionally act as bioenergetic hubs fueling cellular activity. Loss of mitochondrial integrity and function not only deprives T cells of necessary energy reserves but also orchestrates shifts in gene expression that anchor these cells in a dysfunctional, non-proliferative state. Despite recognition of this connection, the mechanistic link between mitochondrial damage and transcriptional reprogramming remained obscure until recently. A groundbreaking study spearheaded by Yingxi Xu and Ping-Chih Ho at Ludwig Lausanne unveils the intricate molecular cascade connecting mitochondrial demise to T cell exhaustion, spotlighting the pivotal role of heme signaling.

This newly elucidated pathway identifies heme—a porphyrin ring-containing iron molecule historically noted for its role in oxygen transport—as a hitherto unrecognized agent facilitating T cell dysfunction. Typically embedded within mitochondrial proteins, heme becomes aberrantly released amidst mitochondrial degradation failures endemic to exhausted T cells in the TME. Xu and colleagues demonstrate that the proteasome, the cell’s principal protein degradation machinery, becomes hyperactivated under these conditions and preferentially dismantles mitochondrial heme-containing proteins. This selective degradation engenders an intracellular surge of free heme, which is subsequently converted into a distinct regulatory form.

The regulatory heme translocates into the nucleus via the transporter protein PGRMC2, where it exerts profound effects on gene expression by inducing degradation of a key transcription factor. This event triggers a cascade of molecular alterations culminating in the activation of exhaustion-associated genetic programs. Intriguingly, the researchers showed that genetic ablation of PGRMC2 interrupts this deleterious sequence, preserving T cells in a metabolically and functionally resilient state. Such findings highlight PGRMC2 as a promising therapeutic target for reinvigorating anti-tumor immunity.

Innovatively, this work also bridges these mechanistic insights to clinical immunotherapeutic strategies, particularly the chimeric antigen receptor (CAR) T cell therapy paradigm. CAR-T therapy, a transformative approach in cancer treatment whereby patient-derived T cells are engineered ex vivo to target cancer-specific antigens, often succumbs to similar exhaustion pathways post-infusion, limiting its long-term efficacy. Xu and Ho’s team employed a pharmacological intervention using bortezomib, a proteasome inhibitor conventionally approved for leukemia treatment, during the CAR-T cell manufacturing process. Remarkably, transient, low-dose administration of bortezomib curtailed exhaustion-associated transcriptional programs within CAR-T cells, fostering a durable intracellular milieu conducive to sustained proliferation and cytotoxic performance.

Clinical correlations further substantiated these preclinical observations. Analysis of CAR-T cells from B cell acute lymphoblastic leukemia (B-ALL) patients revealed that heightened proteasome activity within these cells portended poorer therapeutic outcomes, whereas diminished activity correlated strongly with complete remission and favorable prognoses. This underscores the potential for proteasome modulation as a biomarker and interventional target in enhancing CAR-T efficacy.

The study compellingly reframes T cell exhaustion, not merely as an irreversible endpoint of chronic antigenic stimulation, but as a reversible metabolic and signaling imbalance amenable to therapeutic correction. By dissecting the molecular interplay involving mitochondrial heme processing and proteasomal dynamics, this research provides a conceptual foundation for next-generation cellular immunotherapies aimed at reinvigorating T cell function. These approaches could substantially elevate the potency of immuno-oncology regimens, transforming resistant cancers into tractable diseases.

Furthermore, the implications of their findings extend beyond cancer, potentially influencing fields where T cell exhaustion is implicated, including chronic infections and autoimmune disorders. The integration of metabolic signaling pathways with gene regulation elucidates fundamental principles of immune cell biology that could inspire novel interventions across diverse therapeutic landscapes.

This pioneering investigation was underpinned by a vast network of support from numerous prestigious entities, including the Ludwig Institute for Cancer Research and the Swiss National Science Foundation, evidencing the collaborative efforts propelling advances in cancer immunology. The research outcomes published in Nature exemplify the power of molecular insights to unlock new horizons in immunotherapy.

In summary, Xu, Ho, and colleagues reveal that dysfunctional mitochondrial accumulation triggers a proteasome-dependent heme signaling axis, driving T cell exhaustion through transcriptional reprogramming mediated by regulatory heme and PGRMC2. This discovery not only unveils critical mechanistic underpinnings but also delineates actionable targets such as PGRMC2 and proteasome function modulation with existing drugs like bortezomib. These interventions promise to fortify the metabolic and functional fitness of tumor-targeting T cells, offering renewed hope for durable immune-mediated cancer control.

Subject of Research: Molecular mechanisms underlying T cell exhaustion in cancer and strategies to enhance immunotherapy

Article Title: Proteasome-guided haem signalling axis contributes to T cell exhaustion

News Publication Date: 18 March 2026

Web References:
https://www.nature.com/articles/s41586-026-10250-y

Image Credits: Ludwig Cancer Research

Keywords: T cell exhaustion, cancer immunotherapy, tumor microenvironment, mitochondrial dysfunction, heme signaling, proteasome, CAR-T therapy, PGRMC2, proteasome inhibition, bortezomib, metabolic reprogramming, transcriptional regulation

Tumors create a milieu rife with hypoxia (low oxygen), acidity, nutrient deprivation, and molecular toxins, all of which converge to strain the mitochondria within T cells. Mitochondria, colloquially known as the cell’s powerhouses, are responsible for generating the energy required to carry out immune functions. Under tumor-induced stress, mitochondrial dysfunction occurs, leading to the excessive production of reactive oxygen species (ROS). These ROS are chemically reactive molecules that, at high levels, can inflict severe damage on cellular components including DNA, proteins, and lipids.

The new study, published in the esteemed journal Immunity, illuminates a critical link between mitochondrial ROS generation and telomeric damage in T cells. Normally, telomeres serve as protective caps at chromosome ends, preventing genomic instability and cellular aging. However, the research team discovered that ROS generated by dysfunctional mitochondria migrate into the nucleus and preferentially damage telomeres. This triggered a cascade of cellular signals that push T cells toward exhaustion—a state in which immune cells lose their potency, limiting their ability to attack cancer effectively.

Assistant Professor Dayana Rivadeneira, the study’s lead author, emphasized the therapeutic implications of their findings. By employing a precisely targeted antioxidant that specifically shields telomeres from oxidative damage, they were able to restore T cell functionality in mouse models. “What’s remarkable is that we can intercept the damage process at the telomere level and effectively ‘rescue’ the immune cells,” Rivadeneira explained. This nuanced approach differentiates itself by focusing on telomere stability rather than broadly targeting mitochondrial dysfunction or ROS systemically.

The researchers initially embarked on their investigation with a focus on mitochondrial damage and its influence on T cell performance. Their work unexpectedly expanded into telomere biology through collaboration with experts in molecular pharmacology and chemical biology. Together, they devised a sophisticated genetic mouse model capable of generating controlled amounts of oxidative damage localized only to either mitochondria or telomeres using far-red light activation. This methodological innovation allowed for unprecedented precision in dissecting the crosstalk between cellular powerhouses and the nuclear genome.

Their experiments revealed a fascinating bidirectional communication between mitochondria and telomeres. Damaging mitochondria led to rapid telomeric impairment, and conversely, direct telomere damage sent distress signals back to the mitochondria, effectively instructing the cell to shut down and enter exhaustion. “It illustrates a feedback loop that was previously unappreciated, especially within the immune system,” said senior author Greg Delgoffe. This paradigm-shifting insight reveals telomeres not simply as passive chromosome end-caps but as active participants in regulating cellular energy status and immune cell fate.

At the mechanistic level, the culprit for this vicious cycle appears to be ROS—these reactive molecules that induce oxidative lesions within telomeric DNA. The research team hypothesized that neutralizing ROS specifically at telomeres could break the degenerative loop and preserve T cell efficacy. They engineered a fusion protein combining an antioxidant enzyme with a telomere-binding protein that tethers the protective agent directly at the chromosome ends. This clever molecular design ensured that antioxidant activity was localized precisely where the damage occurs.

When these modified T cells were introduced into mice bearing aggressive melanoma tumors, the results were dramatic. Compared to unmodified T cells, the telomere-antioxidant-protected cells showcased significantly improved survival rates and curtailed tumor growth. This strongly supports the notion that telomere-specific antioxidative strategies can reinvigorate exhausted T cells and bolster anti-tumor immunity. Such findings pave the way for integrating this approach into existing immunotherapeutic modalities.

One particularly promising application is in the realm of chimeric antigen receptor T cell (CAR-T) therapy, a rapidly advancing cancer treatment that involves genetically engineering a patient’s own T cells to target tumors more aggressively. “By incorporating telomere protection into the CAR-T cell production pipeline, we can enhance their durability and potency within the hostile tumor microenvironment,” Delgoffe said. This dual genetic engineering may substantially improve patient outcomes by creating T cells resistant to the common pitfalls imposed by oxidative stress.

Looking forward, Rivadeneira’s laboratory is developing protocols to apply telomere-specific antioxidant strategies to human T cells, inching closer to clinical translation. The potential to amplify and sustain T cell function in cancer patients could revolutionize immunotherapy approaches. Furthermore, her lab plans to explore the broader implications of telomere health on systemic immunity and cancer progression, including how conventional treatments like chemotherapy might inadvertently impair immune resilience by damaging telomeres.

Understanding the interplay between chemotherapy-induced telomere damage and immune cell exhaustion may also explain variability in patient responses to immunotherapies. If chemotherapy diminishes T cell function via telomeric instability, adjunct treatments focusing on telomere maintenance might substantially improve therapeutic efficacy. The implications of this line of research extend beyond oncology, potentially influencing how we approach immune aging and chronic immune deficiencies at large.

This comprehensive study situates telomere integrity at the heart of immune cell endurance within tumors. By illuminating the previously underappreciated molecular dialogue between mitochondria and telomeres mediated by oxidative stress, it opens new frontiers for targeted therapeutic interventions. The capacity to protect T cells against telomeric damage offers a fresh vantage point to bolster immune function where it matters most—with profound implications for cancer treatment and beyond.

Subject of Research: T cell dysfunction in cancer driven by oxidative stress-induced telomere damage

Article Title: Oxidative-stress-induced telomere instability drives T cell dysfunction in cancer

News Publication Date: 9-Sep-2025

Web References: https://www.sciencedirect.com/science/article/pii/S1074761325003711

References: DOI 10.1016/j.immuni.2025.08.008

Image Credits: Rivadeneira et al. (2025) Immunity

Keywords: Telomeres, Immunotherapy, Cancer, Immunology, T cell deficiency, Mitochondria, DNA damage, DNA, Antioxidants